Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Update

Key Points

• Vor Biopharma Inc. experienced a dramatic increase in short interest, rising by 55,636.4% in July, reaching a total of 14,380,000 shares shorted as of July 15th.
• The stock is currently trading at $2.10 with a market cap of $262.42 million and a P/E ratio of -1.39.
• Analysts' ratings for Vor Biopharma are mixed, with one firm upgrading the stock to a "strong-buy" while another rated it a "strong sell."

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 14,380,000 shares, agrowthof55,636.4% from the June 30th total of 25,800 shares. Approximately22.2% of the company's shares are short sold. Based on an average trading volume of 17,340,000 shares, the short-interest ratio is presently 0.8 days. Based on an average trading volume of 17,340,000 shares, the short-interest ratio is presently 0.8 days. Approximately22.2% of the company's shares are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on VOR. HC Wainwright upgraded shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 30th. Wall Street Zen downgraded shares of Vor Biopharma to a "strong sell" rating in a research note on Saturday, June 28th.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock traded up $0.10 during trading on Tuesday, hitting $2.21. 1,269,798 shares of the company's stock were exchanged, compared to its average volume of 8,115,218. Vor Biopharma has a 52-week low of $0.13 and a 52-week high of $3.29. The stock has a market cap of $279.87 million, a PE ratio of -1.46 and a beta of 2.06.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.